A phase I trial of the combination of sirolimus and SU11248 (Sutent(R)) [sunitinib] in patients with advanced solid tumors that are non-curable with standard therapy
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2016
At a glance
- Drugs Sirolimus; Sunitinib
- Indications Solid tumours
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 21 Dec 2013 Status changed from active, no longer recruiting to discontinued.
- 03 Oct 2008 Planned end date changed from 1 Oct 2008 to 1 Dec 2008.